Femoral Bone Metastases
Primary Purpose
Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Surgery Alone
Combined Surgery and Radiation therapy
Sponsored by
About this trial
This is an interventional other trial for Cancer focused on measuring Bone Metastases, Femoral Metastases
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed diagnosis of malignancy other than lymphoma
- Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or more)
- At least 18 years of age
- Able to provide written informed consent
- Able to participate in follow-up
Exclusion Criteria:
- Surgical consultation for the purpose of obtaining a tissue/histological diagnosis only, not for treatment
- Histological diagnosis of lymphoma
Sites / Locations
- Mount Sinai HospitalRecruiting
- University Health Network, Princess Margaret HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Surgery Alone
Surgery + Radiation Therapy
Arm Description
Outcomes
Primary Outcome Measures
To describe the ambulatory status at 3 months by intervention (surgery ± radiotherapy, and radiotherapy alone group) - Ambulatory status
Patient will be assessed at baseline, 6 weeks, 3 months and 6 months
Secondary Outcome Measures
To describe patterns of management in patients with femoral metastases at high risk of pathological fracture - Perioperative Morbidity and Mortality for surgical patients; pain score and performance status; QOL
Patients will be assessed at baseline, 6 weeks, 3 months and 6 months
To describe patient and disease characteristics of major management groups (surgery ± radiotherapy, radiotherapy alone due to preference, radiotherapy alone due to co-morbid conditions) - Assessment of lower limb function
Patient will be assessed at baseline, 6 weeks, 3 months, and 6 months.
Full Information
NCT ID
NCT01428895
First Posted
May 19, 2011
Last Updated
April 5, 2023
Sponsor
University Health Network, Toronto
1. Study Identification
Unique Protocol Identification Number
NCT01428895
Brief Title
Femoral Bone Metastases
Official Title
A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 2009 (undefined)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Health Network, Toronto
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Bone is a common site of metastasis for a range of malignancies. Bone metastases have the potential to cause significant morbidity including pain, impairment of ambulation and reduced functional independence. Previous research has shown that pathological fractures are observed in 9 to 29 percent of patients with long bone metastases, and a high proportion of these require surgical intervention to relieve pain and restore function.
The goal of this study is to describe the clinical outcomes of patients with femoral metastases at high risk of pathological fracture. Patients referred for treatment of femoral metastases at high risk of fracture will be followed prospectively after undergoing with surgery (± post-operative radiotherapy), or radiotherapy alone. Patient and disease characteristics, ambulatory status and limb function will be documented before treatment. These Clinical outcomes of participants in each treatment group will be measured 6 weeks after treatment, and 3- and 6 months after enrolment, with particular reference to patient-reported outcomes relating to pain, ambulatory status, limb function and quality of life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture
Keywords
Bone Metastases, Femoral Metastases
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Surgery Alone
Arm Type
Active Comparator
Arm Title
Surgery + Radiation Therapy
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Surgery Alone
Intervention Description
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Intervention Type
Other
Intervention Name(s)
Combined Surgery and Radiation therapy
Intervention Description
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Primary Outcome Measure Information:
Title
To describe the ambulatory status at 3 months by intervention (surgery ± radiotherapy, and radiotherapy alone group) - Ambulatory status
Description
Patient will be assessed at baseline, 6 weeks, 3 months and 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To describe patterns of management in patients with femoral metastases at high risk of pathological fracture - Perioperative Morbidity and Mortality for surgical patients; pain score and performance status; QOL
Description
Patients will be assessed at baseline, 6 weeks, 3 months and 6 months
Time Frame
6 months
Title
To describe patient and disease characteristics of major management groups (surgery ± radiotherapy, radiotherapy alone due to preference, radiotherapy alone due to co-morbid conditions) - Assessment of lower limb function
Description
Patient will be assessed at baseline, 6 weeks, 3 months, and 6 months.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed diagnosis of malignancy other than lymphoma
Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or more)
At least 18 years of age
Able to provide written informed consent
Able to participate in follow-up
Exclusion Criteria:
Surgical consultation for the purpose of obtaining a tissue/histological diagnosis only, not for treatment
Histological diagnosis of lymphoma
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca Wong, MB ChB
Phone
416 946 4501
Ext
2126
Email
Rebecca.wong@rmp.uhn.on.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rebecca Wong, MB ChB
Organizational Affiliation
University Health Network, Princess Margaret Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter Ferguson, MD
Organizational Affiliation
Mount Sinai Hospital, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Ferguson, MD
Phone
416 586-4800
Ext
8687
Email
PFerguson@mtsinai.on.ca
Facility Name
University Health Network, Princess Margaret Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Wong, MB ChB
Phone
416 946 4501
Ext
2126
Email
Rebecca.Wong@rmp.uhn.on.ca
12. IPD Sharing Statement
Learn more about this trial
Femoral Bone Metastases
We'll reach out to this number within 24 hrs